Search

Health Canada has approved Merck's KEYTRUDA(R) pembrolizumab for the treatment of adult patients with resectable Stage II, IIIA, or IIIB T3-4N2 non-small cell lung carcinoma NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment. The approval is based on the Phase 3 KEYNOTE-671 trial, showing significant results in event-free survival and overall survival. This approval provides a new therapeutic option for patients with operable non-small cell lung cancer, aiming to improve patient outcomes and expand treatment options in Canada. [Extracted from the article]

Researchers from the Chinese University of Hong Kong conducted a retrospective review of patients with choroidal metastasis from non-small-cell lung carcinoma between 2013 and 2023. The study compared outcomes of targeted therapy versus conventional radiotherapy and/or chemotherapy, finding that tyrosine kinase inhibitor monotherapy showed rapid visual recovery and durable disease control in patients with epidermal growth factor receptor mutation-positive non-small-cell lung carcinoma. The research suggests that tyrosine kinase inhibitors could be considered as an alternative to conventional treatments for these patients. [Extracted from the article]

A recent study conducted at the Medical College of Soochow University focused on the crosstalk between SND1 and PDCD4 in non-small cell lung cancer (NSCLC) cells and its association with chemoresistance. The research highlighted the role of SND1 in regulating chemoresistance in NSCLC cells and how silencing SND1 increased sensitivity to chemotherapeutic drugs. The study concluded that understanding the correlation between SND1 and PDCD4 could provide insights into the mechanisms of chemoresistance in NSCLC. For more information, the full article can be accessed at the Cell Death Discovery website. [Extracted from the article]

Researchers at the University of Health Sciences in Turkey conducted a study on the relationship between Sirtuin 1 and Sirtuin 2 expression and clinicopathological parameters in non-small cell lung cancer (NSCLC) patients. The study found that high levels of SIRT2 expression were associated with longer overall survival, and that high expression of both SIRT1 and SIRT2 correlated with longer survival times. The research suggests that SIRT1 and SIRT2 may suppress tumor growth in NSCLC and serve as positive prognostic indicators. [Extracted from the article]

A recent study conducted by researchers at Kurume University School of Medicine focused on the efficacy and safety of chemoradiotherapy (CRT) combined with local consolidative therapy (LCT) for patients with Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases. The study enrolled 19 patients and found that the treatment approach resulted in a 2-year survival rate of 68.4% and a response rate of 58%. The researchers concluded that this combined treatment strategy may extend survival and achieve local control for NSCLC with oligometastases. [Extracted from the article]

Researchers from Harbin Medical University Cancer Hospital conducted a study on non-small cell lung cancer (NSCLC) to identify new biomarkers for treatment strategies. They focused on immunogenic cell death (ICD) genes to predict patient outcomes and immune infiltration status. By analyzing 17 specific genes, they developed a prognostic risk model that could accurately predict patient prognosis and susceptibility to immune-checkpoint blockade treatment. This research could lead to the development of new targeted treatments for NSCLC. [Extracted from the article]

Researchers from Nanjing Normal University in China have conducted a study on small cell lung cancer, focusing on the role of the enzyme METTL3 in promoting tumor growth. The study found that METTL3 inhibits the RIG-I-MAVS innate immune pathway, which plays a crucial role in immune defense against cancer cells. This research provides new insights for potential biotherapy and immunotherapy strategies in treating non-small-cell lung carcinoma. [Extracted from the article]

A recent study from the University of Louisville explores the impact of PFKFB3 inhibition on the adaptivity of lung cancer cells to EGFR TKI therapies. The research reveals that inhibiting PFKFB3 can reduce glucose utilization and DNA damage repair, limiting the adaptivity of cells to therapy-driven oxidative stress and DNA integrity insults. These findings suggest that targeting PFKFB3 could be an effective strategy to eradicate cancer cells surviving under EGFR TKI therapy and may have implications for developing new therapies for drug-resistant cancer treatment. [Extracted from the article]

A recent report from the University of Cote d'Azur in Nice, France, discusses the potential of using minimal residual disease (MRD) assessment in patients with resected non-small cell lung carcinoma (NSCLC) to optimize patient care. The evaluation of MRD status could lead to improved overall survival and help determine the need for adjuvant therapies. The study emphasizes the importance of bridging the gap between clinical research and routine MRD evaluation in daily practice, providing recommendations for optimizing MRD assessment in non-small cell lung cancers. [Extracted from the article]

A recent study from Duke University School of Medicine explores the combination of laser interstitial thermal therapy (LITT) and immune checkpoint blockade (ICB) in patients with non-small cell lung cancer (NSCLC) brain metastases. The research found that the combination of LITT and ICB did not compromise procedural outcomes or time to steroid discontinuation in NSCLC patients. The study suggests that prospective studies are needed to further assess biomarkers of immune response in this treatment approach. [Extracted from the article]

Researchers at Baylor University College of Medicine have found that combining oncolytic viruses (OVs) derived from non-human host viruses with chimeric antigen receptor-modified T cells (CAR-T cells) enhances anti-tumor activity in models of non-small cell lung carcinoma (NSCLC). The study showed that the combination of OVs and CAR-T cells led to superior control of NSCLC tumors compared to either agent alone. This research, funded by organizations such as AstraZeneca and the National Institutes of Health, has been peer-reviewed and published in Molecular Therapy Oncology. [Extracted from the article]

A new study published by researchers at the Institute of Aerospace Medicine in Cologne, Germany, explores the impact of chronic hypoxia on non-small cell lung cancer cells exposed to X-rays. The study found that chronic hypoxia increased the radioresistance of the cancer cells, affecting cell survival, DNA damage, cell cycle distribution, cytokine secretion, and gene expression. Despite the absence of functional p53, the cells exhibited radioresistance related to various cellular processes under chronic hypoxia. This research sheds light on the complex interactions between hypoxia, DNA damage, and inflammatory responses in non-small cell lung cancer cells. [Extracted from the article]

A recent study conducted at University Hospital Grenoble Alpes in La Tronche, France, focused on the management of locoregional recurrences in non-small cell lung cancer patients after initial radiotherapy. The study highlighted the importance of salvage radiotherapy treatment in these cases, emphasizing patient selection, dosimetric aspects, and associated uncertainties. The research, which has been peer-reviewed, provides valuable insights into this therapeutic modality for recurrent non-small cell lung carcinomas. [Extracted from the article]

The article discusses a Phase 1a/1b clinical trial, NCT06685718, evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of BG-60366 in patients with EGFR-mutant Non-Small Cell Lung Cancer (NSCLC). BG-60366 is a compound designed to degrade mutant EGFR, a common cause of NSCLC. The study aims to assess the effectiveness of BG-60366 in participants with advanced or metastatic EGFR-mutant NSCLC through two phases: Dose Escalation and Safety Expansion, and Dose Expansion. [Extracted from the article]

A patent application titled "Treatment Of Nsclc Patients With Tumor Infiltrating Lymphocyte Therapies" was published online on November 7, 2024, by inventors FARDIS, Maria and VON FINCKENSTEIN, Friedrich Graf Finck. The application addresses the urgent need for new treatment options for non-small-cell lung cancer (NSCLC) patients, focusing on the use of tumor infiltrating lymphocytes (TILs) for refractory cases. The method involves obtaining TILs from a tumor sample, expanding them in a closed system, and administering them to patients who are resistant to immune-checkpoint inhibitor (ICI) treatment. This innovative approach aims to provide a viable therapeutic option for NSCLC patients with limited treatment choices. [Extracted from the article]

Researchers at the San Juan Bautista School of Medicine have conducted a study on the potential anticancer effects of the iron chelator Deferasirox (Def) on non-small cell lung carcinoma (NSCLC). The study found that Def induced cytotoxicity, chelated intracellular iron, triggered apoptosis, and inhibited cell migration and chemoresistance markers in NSCLC cells. In vivo experiments on a lung carcinoma mouse model showed a significant decrease in tumor growth with Def treatment, suggesting its anti-metastatic and anti-chemoresistance effects. This research provides insights into the molecular targets and mechanisms of Def in lung carcinoma, particularly within iron-related pathways. [Extracted from the article]

A recent study conducted at Vardhman Mahavir Medical College and Safdarjung Hospital focused on the prevalence of epidermal growth factor receptor (EGFR) gene mutations in north Indian patients with non-small cell lung carcinoma (NSCLC). The research found a 15% mutation frequency in the study sample, with diverse genetic and ethnic factors potentially contributing to the uncommon variants observed. The study suggests the need for future genome-wide association studies to identify genetic polymorphisms that could impact treatment and prevention of NSCLCs in different ethnic populations. [Extracted from the article]

The article discusses the clinical utility of carbonic anhydrase IX (CAIX) expression as a diagnostic marker for distinguishing pleural mesothelioma from non-small cell lung carcinoma (NSCLC). The study found that CAIX expression had high sensitivity in detecting pleural epithelioid mesothelioma, comparable to or better than currently used markers. The specificity of CAIX was also within a comparable range to commonly used markers, making it a valuable tool for the differential diagnosis of mesothelioma from NSCLC. The study was recently published in the Journal of Clinical and Translational Pathology, the official scientific journal of the Chinese American Pathologists Association (CAPA). [Extracted from the article]

A patent has been issued for methods for early detection of cancer by Guardant Health Inc., focusing on high sensitivity detection of genetic variants in cell-free DNA samples. The methods involve sequencing panels of genes to detect tumor markers associated with various cancers, including non-small cell lung carcinoma. The patent outlines techniques for enriching and sequencing cfDNA to identify residual disease in patients who have undergone cancer treatment. This innovative approach aims to improve outcomes through early cancer detection. [Extracted from the article]

A recent report from the Chinese University of Hong Kong discusses the cellular dynamics of the tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma. The study highlights the role of immune/stromal cells in modulating treatment responses and explores how these interactions contribute to resistance. The research aims to identify novel therapeutic targets and strategies to enhance the efficacy of immune checkpoint inhibitors in treating non-small cell lung cancer. [Extracted from the article]

Researchers at West Virginia University have submitted a patent application for a method involving microRNAs to improve the diagnosis and treatment of lung and breast cancer. The application focuses on identifying miRNAs associated with lung and breast cancer, developing accurate classifiers for tumor detection, and identifying potential drug targets for treatment. The research aims to enhance early diagnosis, improve patient survival rates, and explore new therapeutic strategies for these types of cancer. The patent application highlights the potential of miRNAs as diagnostic biomarkers and therapeutic targets in cancer research. [Extracted from the article]

Researchers from Guizhou Medical University have developed a deep learning model to predict the response of non-small cell lung carcinoma (NSCLC) patients to concurrent chemoradiotherapy (CCRT). The model, based on contrast-enhanced computed tomography (CT) images, showed promising predictive performance with an area under the curve of 0.86 in the training cohort and 0.84 in the validation cohort. The study also explored biological signaling pathways associated with the DL model and found it to be positively related to cell adhesion molecules, the P53 signaling pathway, and natural killer cell-mediated cytotoxicity. This research contributes to understanding treatment responses in NSCLC patients undergoing CCRT. [Extracted from the article]

A patent application has been filed for a shortened manufacturing process to generate tumor infiltrating lymphocytes (TILs) for the treatment of non-small cell lung carcinoma (NSCLC) patients who are resistant to anti-PD-1 treatment. The method involves obtaining TILs from a NSCLC tumor, expanding them in cell culture medium, and administering them to the patient. The refractory NSCLC may have been previously treated with anti-PD-1 antibodies or chemotherapeutic agents, and may have low expression of PD-L1 or bulky disease. This process aims to provide a viable treatment option for patients with limited options. [Extracted from the article]

A recent study conducted by researchers at Fu Jen Catholic University in New Taipei, Taiwan, explored the role of the inhibitor of DNA-binding 2 (ID2) in non-small cell lung cancer (NSCLC). The study found that ID2 expression is inversely correlated with NSCLC cell invasiveness. The researchers overexpressed ID2 in H1299 cells and discovered that it effectively inhibited migration, invasion, proliferation, and colony formation abilities. They also identified the basal promoter region of ID2 and examined the DNA methylation status of the ID2 promoter. The study suggests that the transcription factor Yin Yang 1 (YY1) may play a crucial role in regulating ID2 expression and repressing cancer cell growth. [Extracted from the article]

A recent study conducted at the Netherlands Cancer Institute has provided new insights into small cell lung cancer. The study focused on the diagnosis and treatment of leptomeningeal metastases (LM) in patients with epidermal growth factor receptor mutation-positive (EGFRm +) non-small-cell lung carcinoma (NSCLC). The researchers aimed to identify resistance mechanisms (RM) to osimertinib in cerebrospinal fluid (CSF) and plasma. The study found that 27% of patients had an RM in CSF ctDNA, and the clinical efficacy of osimertinib dose escalation (DE) was limited. The researchers concluded that there is still much to learn about diagnostic and therapeutic strategies for EGFRm + NSCLC LM. [Extracted from the article]

A recent study conducted at the Mayo Clinic in Rochester, Minnesota aimed to determine the associations between MYC immunoreactivity, MYC copy number gain (CNG), driver mutations, and survival in patients with non-small cell lung cancer (NSCLC) treated with immunotherapy. The study found that positive MYC immunohistochemistry (IHC) was significantly associated with KRAS mutation and current/former smoking, while MYC CNG was significantly associated with STK11 mutation. Positive MYC IHC was identified as an independent predictor of shorter overall survival (OS) after immunotherapy treatment, particularly in cases with MYC positive/PD-L1 < 1% status. The researchers suggest that positive MYC IHC may be relevant to NSCLC treatment selection and future therapy development. [Extracted from the article]

A recent report from the Institut de Cancerologie Strasbourg Europe in France discusses the challenges of managing non-small cell lung cancer (NSCLC) with brain metastases (BM) as the initial sign. The study analyzed 25 patients with newly diagnosed brain metastatic NSCLC without specific genetic alterations. The findings suggest that patients with symptomatic BM as the first sign and those with oligometastatic disease have better prognosis. The study also highlights the potential benefits of combining local approaches with first-line immune checkpoint inhibitors (ICI) and chemotherapy in improving survival outcomes for brain metastatic NSCLC. [Extracted from the article]

A patent application has been submitted for the approval of formulations of anti-PD1 antibodies. PD-1 is a cell surface protein that regulates immune responses, and inhibiting its interaction with PD-L1 can enhance T cell responses and mediate antitumor activity. Several antibodies targeting PD-1 have been developed, including pembrolizumab and nivolumab. The patent application describes liquid pharmaceutical compositions containing an anti-PD1 antibody, amino acids, a non-ionic surfactant, and citrate buffer, with a pH between 5.0 and 5.8. These compositions may be used for the treatment of various cancers. [Extracted from the article]

The article focuses on the relationship between periostin expression and pro-angiogenic factors in non-small-cell lung carcinoma (NSCLC). Topics include the correlation of periostin with factors such as CD31, CD34, CD105, and VEGF-A, its impact on microvascular density and tumor progression, and its potential role as a prognostic marker in NSCLC.

A recent study conducted by researchers from the All India Institute of Medical Sciences (AIIMS) in New Delhi, India, focused on the detection of biomarkers in advanced lung adenocarcinomas. The study evaluated the utility of ALK and ROS1 fluorescence in situ hybridization (FISH) as a complement to immunohistochemistry (IHC) in routine predictive biomarker testing algorithms. The results showed that immunostaining is a robust method for ALK rearrangement testing, with FISH adding value in rare equivocal cases. Additionally, the study found that ROS1 rearrangement testing is more cost-effective if IHC is followed by FISH after excluding EGFR-mutant and ALK-rearranged adenocarcinomas. [Extracted from the article]

A patent application titled "A Method To Identify Exceptional Anti-Tumor Benefit From Braf Targeted Therapies" has been published online. The inventor, Hans Ragnar Widlund, proposes a method for determining whether a cancer patient is likely to benefit from treatment with a BRAF inhibitor. The method involves evaluating the presence and level of GAPDHS in a sample of cancer cells and comparing it to a reference level. If the level of GAPDHS is equal to or greater than the reference level, there is a high likelihood of response to the treatment. The patent application also includes methods for treating cancer patients who have been identified as likely to benefit from BRAF inhibitors. The invention aims to personalize precision medicines for improved cancer care. [Extracted from the article]

A study conducted at the First Affiliated Hospital in Shandong, China, examined the real-world outcomes of patients with advanced non-small cell lung cancer (NSCLC) who were treated with immune checkpoint inhibitor (ICI)-based regimens. The study found that patients with a PD-L1 tumor proportion score (TPS) of >= 50% had favorable progression-free survival (PFS) and overall survival (OS) when treated with ICIs plus chemotherapy. Additionally, the study identified other factors, such as clinical stage, previous systemic therapy, and metastases, that were associated with PFS and OS. These findings suggest that immunotherapy is an effective treatment strategy for advanced NSCLC, particularly in patients with a high PD-L1 TPS. [Extracted from the article]

Researchers at the All India Institute of Medical Sciences (AIIMS) in New Delhi have conducted a study on the detection of epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer (NSCLC). The study compared the use of liquid biopsy (testing plasma cell-free DNA) with tissue biopsy for detecting EGFR mutations. The researchers found that the liquid biopsy approach had a shorter turnaround time and comparable outcomes to tissue biopsy, making it a reliable method for detecting EGFR mutations in advanced-stage NSCLC. This research provides valuable insights into improving the diagnosis and treatment of NSCLC. [Extracted from the article]

A recently published patent application titled "Methods For Early Detection Of Cancer" outlines a system for detecting cancer at an early stage. The method involves analyzing cell-free DNA from a patient and sequencing it to identify genetic variants associated with specific types of cancer. The application highlights several cancers that can be detected using this method, including ovarian, pancreatic, breast, colorectal, and non-small cell lung carcinoma. The application provides detailed information on the techniques and applications of the method, which has high sensitivity and specificity in detecting tumor markers at low frequencies. [Extracted from the article]

Toray Industries Inc. has been granted a patent for a kit, device, and method to detect lung cancer. The patent provides background information on lung cancer and its different tissue types. The inventors aim to identify a new tumor marker for lung cancer that can be used in initial tests and offer an effective method for detecting the disease using specific nucleic acids. The patent claims a method to detect and treat lung cancer by determining the expression level of hsa-miR-4730 in a sample from a human subject, such as blood, serum, or plasma. Treatment options include chemotherapy, radiotherapy, immunotherapy, molecular targeted therapy, surgery, or a combination of these. The patent also describes a method to detect lung cancer using specific nucleotide sequences, measuring the expression levels of certain microRNAs associated with the disease. The measurement can be done using quantitative RT-PCR or hybridization techniques. The patent also mentions other microRNAs that can be measured to determine the expression levels of additional lung cancer markers. Overall, this patent provides a kit, device, and method for detecting lung cancer. [Extracted from the article]

A researcher at University Hospital Martin in Slovakia has published new findings on small cell lung cancer. The study focused on the detection of anaplastic lymphoma kinase (ALK) in non-small cell lung carcinoma (NSCLC) cases. The researchers used immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) analyses to compare discordant and concordant samples. The study found that FISH analysis was able to detect atypical or heterogeneous patterns of ALK rearrangement in cases with negative protein expression, suggesting more extensive genetic alterations rather than true ALK rearrangement. [Extracted from the article]

A case series study conducted at Northwestern University in Chicago, Illinois, explored the use of double lung transplantation (DLT) as a potential curative treatment for patients with metastatic lung-limited non-small cell lung carcinoma (NSCLC). The study included six patients with stage IVA NSCLC who underwent DLT. The patients had high oxygen requirements before the transplant due to cancer progression, but after the procedure, none of them required oxygen therapy. All six patients were alive and in good health at the time of the study. The ongoing DREAM study aims to further investigate the role of DLT in metastatic lung-limited NSCLC patients. [Extracted from the article]

A recent report from Taylor's University in Selangor, Malaysia discusses the role of genetic polymorphisms in non-small cell lung carcinoma (NSCLC) susceptibility and survival. NSCLC is the most common type of lung cancer and is associated with poor prognosis. The study focuses on the impact of single nucleotide polymorphisms (SNPs) in immunomodulatory markers on NSCLC risk and prognosis. The findings provide valuable insights into the genetic factors influencing NSCLC and may contribute to personalized clinical care for patients. [Extracted from the article]

A study conducted at Nice University Hospital in France explored the use of RNA next-generation sequencing (NGS) as a reflex test for identifying ALK fusions in non-small cell lung cancer (NSCLC). The researchers aimed to replace ALK immunohistochemistry (IHC) with RNA NGS in the screening process. The evaluation included 1246 NSCLC cases, and RNA NGS detected ALK alterations in 59 cases (4.8%). The study concluded that replacing systematic ALK IHC screening with RNA NGS reflex testing could provide a more comprehensive and accurate assessment of ALK status. [Extracted from the article]

A recent study conducted by Dalian Medical University investigated the prognostic significance of the advanced lung cancer inflammation index (ALI) in patients with operable non-small cell lung carcinoma (NSCLC). The study included 899 patients with non-small cell lung cancer who underwent surgery between January 2017 and June 2021. The researchers found that ALI can be used as a reliable indicator to evaluate the prognosis of patients with operable NSCLC. By constructing a nomogram model, the study aims to facilitate better individualized treatment and prognosis assessment for patients with NSCLC. [Extracted from the article]

A patent application has been submitted by inventors for a method of early cancer detection using genetic testing. The method involves capturing cell-free nucleic acid molecules from a sample and sequencing them to detect tumor markers associated with specific types of cancer. The inventors claim that their method has high sensitivity and can detect tumor markers at a frequency as low as 0.01%. The patent application includes details about the specific genes and regions that can be targeted for detection, and the methods can be applied to various types of cancer. [Extracted from the article]

A patent application has been filed for methods and systems that can be used for early cancer detection. The methods involve capturing cell-free nucleic acid molecules from a subject and sequencing them to detect tumor markers at a low frequency in the sample. The methods have potential applications for detecting various types of cancer, including ovarian, pancreatic, breast, colorectal, and non-small cell lung carcinoma. Additionally, the patent application describes a method for detecting residual disease in a subject using cell-free DNA sequencing, which can be used to detect genetic variants associated with cancer in subjects who have previously received cancer treatment. The application provides detailed information about the specific techniques and parameters used in the method. [Extracted from the article]

Researchers from Rutgers University - The State University of New Jersey have conducted a study on non-small cell lung carcinoma with clear cell features, a rare histologic presentation of lung carcinoma. The study examined 31 cases and found that the tumors showed a predilection for the right upper and lower lobes. Immunohistochemistry revealed that most cases were typed as adenocarcinoma or squamous cell carcinoma, with a subset of solid adenocarcinoma cases showing a distinctive "pseudosquamous" morphology. Next-generation sequencing identified various molecular alterations, with the most common abnormalities found in the TP53 gene, FGFR gene family, KRAS, AKT1, and BRAF. The study concluded that NSCLC with clear cell features can display aggressive behavior and may require distinguishing from other lung tumors with clear cell morphology. The identification of targetable molecular alterations in some of these tumors may be valuable for therapeutic management. [Extracted from the article]

A study conducted at the University of Belgrade in Serbia explored the impact of tyrosine kinase inhibitors (TKIs) on multidrug resistance (MDR) in non-small cell lung carcinoma (NSCLC). The researchers evaluated the response of 17 patient-derived NSCLC cultures to 10 commonly prescribed TKIs and correlated these responses with patient mutational profiles. The study found that NSCLC cultures responded differently to TKIs, with erlotinib showing good efficacy regardless of mutation burden or EGFR status. However, the modulation of MDR mechanisms by erlotinib, such as increased ABCG2 expression, posed challenges for treatment. The study highlights the importance of considering drug sensitivity, off-target effects, MDR risks, and patient-specific genetic profiles when optimizing NSCLC treatment. [Extracted from the article]

A recent study conducted at the Memorial Sloan-Kettering Cancer Center in New York City has explored the pathologic assessment and staging of multiple non-small cell lung carcinomas (NSCLCs). The research highlights the need for a standardized approach to evaluating and staging these tumors using molecular methods. The study discusses the use of genomic sequencing to identify targetable alterations in NSCLC and the importance of molecular techniques in determining clonal relationships among multiple NSCLCs. The researchers propose a practical approach for evaluating multiple NSCLCs in the clinical setting, taking into account the varying availability of molecular techniques. [Extracted from the article]